anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention provides a Chinese medicine composition for treating vascular dementia. The Chinese medicine composition is prepared from the following Chinese medicine raw materials by weight: 400-600g of prepared fleece flower root, 400-600g of prepared rehmannia root, 300-400g of dogwood, 1200-1500g of herba epimedii and 300-400g of cynomorium songaricum. The inventors perform impact test to a vascular dementia mode mice by repeated cerebral ischemia-reperfusion with the Chinese medicine composition. The test result indicates that repeated cerebral ischemia-reperfusion combined with hemorrhage leads to decrease of learning and memory ability of mice. The Chinese medicine composition provided by the invention can improve the learning and memory ability of mice with quasi VD (Vascular Dementia), enhance ChAT (choline acetyl transferase) activity and reduce AChE (acetylcholin esterase) activity in brains of the mode mice, increase the content of ACh (acetyl choline), reduce the content of SOD (Superoxide Dismutase) in brains of the mode mice, and increase the contents of SOD and GSHpx (glutathione peroxidase). Therefore, the Chinese medicine composition provided by the invention can be used for preparing medicines for treating vascular dementia. The Chinese medicine composition provided by the invention is wide in source of raw materials, simple in preparation method and suitable for industrialized production. The Chinese medicine composition can be directly taken by mixing with water and is convenient to use in clinical application, and has greater clinical application value and social benefit.
Recombinant cultivable mycobacteria capable of expressing DNA of interest which encodes at least one protein antigen against which an immune response is mycobacteria.   In the recombinant mycobacteria, the DNA of interest is stably maintained extrachromosomally or is stably integrated into genomic DNA.  Such recombinant mycobacteria are useful as vehicles to be used as vaccines to provide immunity against a pathogen, as anti-fertility "vaccines" and as a means to nonspecifically augment immune responses to foreign antigens expressed by BCG or to treat human cancers. The present invention also relates to recombinant vectors useful in introducing DNA of interest into mycobacteria, where it is expressed.  One type of vector is a recombinant phasmid capable of replicating as a plasmid in E. coli and of lysogenizing a mycobacterial host.  A second type of vector is a recombinant plasmid which can be introduced into mycobacteria, where it is stably maintained extrachromosomally.  A third type of recombinant vector is one which replicates in E. coli but not in mycobacteria.
The sleep extension group (n=150) will receive a behavioral intervention focusing on parents putting their children to bed earlier by 60-90 minutes. Parents will be instructed only to alter their children's daily sleeping routine, and not to directly alter their diet and physical activity habits. The intervention will be delivered via 2 in-person (weeks 1 and 2) and 4 virtual meetings (weeks 4, 6, 8, and 10).
More specifically, you will have a standard endoscopy during which tissue samples will be taken from the esophagus to check for the severity of the disease. This is part of standard care. If you participate in the study, additional samples will be taken from the esophagus and also from the stomach (a total maximum of 10 samples of 1-2 mm). As a result, the endoscopic examination will take about 10-15 minutes longer than standard. Furthermore, in addition to the tissue samples, cells of the esophageal mucosa will be sampled (through 4 "esophageal brushes") and blood (4 tubes) will also be collected.

For this study, you will be contacted a total of two times. Once for a screening visit and once for the sample collection described above. The screening and sample collection will take place during the already scheduled treatments and consultations. Afterwards, patient outcomes will be documented for the study until a maximum of 5 years after inclusion. This documentation will take place during the routine follow up so does not require any additional visits for the patients.
The present invention provides a method of isolating at least one diterpene alkaloid in particular with anticancer activity from Aconitum carmichaeli. The method can be used to isolate and obtain for example about four diterpene alkaloids of the vakognavine-type and hetisine-type. Among them is a novel vakognavine-type alkaloid which has not been described and isolated so far. Experimental tests confirmed an exceptional cytotoxicity of the vakognavine-type alkaloid against several cancer cell types. Still further, the present invention refers to a method of treating a subject suffering from cancer by administering a pharmaceutical composition comprising at least one diterpene isolated from Aconitum carmichaelii with the method of the present invention. The present invention further refers to a composition, in particular a pharmaceutical composition, comprising the novel vakognavine-type alkaloid, a method for inhibiting, reducing or preventing the proliferation and/or inducing apoptosis of cancer cells by said vakognavine type alkaloid and a method of treating a subject suffering from cancer by administering said vakognavine-type alkaloid to the subject.
PURPOSE: Sleep apnea headache can be defined as a persistent, widespread, throbbing headache that occurs recurrently, is not accompanied by any additional symptoms after waking up, and usually resolves within four hours. Diagnosis of the condition requires confirmation through polysomnography with an apnea-hypopnea index of at least 5, indicating the presence of obstructive sleep apnea syndrome (OSAS). While sleep apnea headaches are common in 10-15% of individuals with OSAS, morning headaches are experienced by 5% of this population. The aim of this study is to examine both polysomnographic and clinical features associated with sleep apnea headache in individuals confirmed to have OSAS by polysomnography.
METHOD: The study was conducted in the sleep center of University of Health Science, Erenköy Mental and Nervous Disease Training and Research Hospital. We have examined the clinical and polysomnographic data of the patients with sleep apnea headache (SAH) diagnosed according to IHS-3 criteria retrospectively and grouped the patients as mild, moderate and severe OSAS. Patients with morning headache except sleep apnea headache and under PAP titration treatment were excluded. The differences between the sleep macro structures of patients with (WSAH) and without sleep apnea headache (WOSAH) were examined.
RESULTS: The WSAH group consisted of 384 participants and the control group (WOSAH) consisted of 294 participants The mean age was 46.29 ± 12.18 and 45.08 ± 12.62 years, respectively. Patients in the WSAH group had significantly higher scores on the Epworth Sleepiness Scale (ESS) (p = 0.004) and higher periodic limb movement index (PLMI) (p = 0.014) compared to the WOSAH group. WSAH patients exhibited shorter wake times after sleep onset (WASO) and lower scores on the sleep quality index, in contrast to WOSAH patients. Additionally, within the WSAH group, there was a negative correlation between age and several sleep parameters, including total sleep parameters. A positive correlation was observed between sleep duration (p = 0.009), waking up after sleep (p = 0.043), sleep efficiency (p = 0.001) and apnea-hypopnea index (AHI) (p = 0.018). Additionally, ESS scores were positively correlated with AHI and total awake time (p = 0.000 and p = 0.008, respectively), while negatively correlated with stage N3 sleep percentage and mean minimum oxygen level (p = 0.001 and p = 0.020, respectively) in the WSAH group.
CONCLUSION: The causes and possible mechanisms of sleep apnea headache are not fully clarified and the underlying processes are not fully understood. Sleep apnea headaches appear to be related to disturbances in nocturnal sleep. Dysregulation in regions that modulate sleep and nociception may be one possible mechanism.
OBJECTIVE: Glucagon-like peptide 1 (GLP-1) receptor agonists reduce food intake, producing remarkable weight loss in overweight and obese individuals. While much of this weight loss is fat mass, there is also a loss of lean mass, similar to other approaches that induce calorie deficit. Targeting signaling pathways that regulate skeletal muscle hypertrophy is a promising avenue to preserve lean mass and modulate body composition. Myostatin and Activin A are TGFβ-like ligands that signal via the activin type II receptors (ActRII) to antagonize muscle growth. Pre-clinical and clinical studies demonstrate that ActRII blockade induces skeletal muscle hypertrophy and reduces fat mass. In this manuscript, we test the hypothesis that combined ActRII blockade and GLP-1 receptor agonism will preserve muscle mass, leading to improvements in skeletomuscular and metabolic function and enhanced fat loss.
METHODS: In this study, we explore the therapeutic potential of bimagrumab, a monoclonal antibody against ActRII, to modify body composition alone and during weight loss induced by GLP-1 receptor agonist semaglutide in diet-induced obese mice. Mechanistically, we define the specific role of the anabolic kinase Akt in mediating the hypertrophic muscle effects of ActRII inhibition in vivo.
RESULTS: Treatment of obese mice with bimagrumab induced a ∼10 % increase in lean mass while simultaneously decreasing fat mass. Daily treatment of obese mice with semaglutide potently decreased body weight; this included a significant decrease in both muscle and fat mass. Combination treatment with bimagrumab and semaglutide led to superior fat mass loss while simultaneously preserving lean mass despite reduced food intake. Treatment with both drugs was associated with improved metabolic outcomes, and increased lean mass was associated with improved exercise performance. Deletion of both Akt isoforms in skeletal muscle modestly reduced, but did not prevent, muscle hypertrophy driven by ActRII inhibition.
CONCLUSIONS: Collectively, these data demonstrate that blockade of ActRII signaling improves body composition and metabolic parameters during calorie deficit driven by GLP-1 receptor agonism and demonstrate the existence of Akt-independent pathways supporting muscle hypertrophy in the absence of ActRII signaling.
The invention discloses stomach-nourishing pain-easing powder used for infants. The stomach-nourishing pain-easing powder is prepared from, by weight, 18-22 parts of Chinese yams, 8-12 parts of flos caryophyllata, 11-13 parts of red dates, 5-7 parts of fructus evodiae and 2-4 parts of lotus seeds. Preferentially, the stomach-nourishing pain-easing powder is prepared from, by weight, 20 g of Chinese yams, 10 g of flos caryophyllata, 12 g of red dates, 6 g of fructus evodiae and 3 g of lotus seeds. The ingredients are mixed according to the proportion and ground into powder to be prepared into powder. In the using process, it is only needed to take an appropriate amount of medicinal powder, add vinegar into the medicinal powder, stir the mixture evenly to be prepared into pills and externally attach one pill to the Shenque acupoint, namely the belly button through dressing, and the pills are additionally attached to the Tianshu acupoint and Zhongwan acupoint for critical patients; according to the dosage, the powder is taken two times per day, and one paste is used each time and used for 6-8 hours. The stomach-nourishing pain-easing powder has the effects of warming the middle, dispelling cold, regulating vital energy and easing pain, is suitable for abdominal pain, diarrhea, dyspepsia, gastrointestinal dysfunction, anorexia and others and has a treatment effect and an assistance effect on mesentery lymphnoditis of the infants.
PURPOSE: A composition for preventing or treating cardiovascular diseases including dioscorea batatas decne extracts is provided to reduce generation of lesion or precipitation of lipid inside aorta. CONSTITUTION: A composition for preventing or treating cardiovascular diseases includes dioscorea batatas decne extracts or rind extract as an active ingredient. The dioscorea batatas decne extracts or rind extract is obtained by extracting dioscorea batatas decne or rind using water, C1-C4 alcohol or a mixed solvent thereof. The dioscorea batatas decne extracts or rind extract is obtained by extracting dioscorea batatas decne or rind using C1-C4 alcohol or a mixed solvent thereof and re-extracting by using hexane. The dioscorea batatas decne extracts or rind extract includes ethyl palmitate, ethyl linoleate, B-sitosterol or a combination thereof. The dioscorea batatas decne extract has inhibition activities for necrotic core inside the blood vessel and fibrosis formation or inflammation due to macrophages.
PURPOSE: Endoscopic surgery is widely accepted for both elective and emergent abdominal surgery. This study was performed to assess the accuracy of preoperative adhesion mapping by abdominal ultrasonography (US).
METHODS: Intra-abdominal intestinal adhesions on the abdominal wall in 50 patients with a history of abdominal surgery were prospectively assessed by the visceral slide test with US before laparoscopic surgery from 2019 to 2022. Adhesion was assessed in six separate abdominal zones during US. Actual adhesion on the abdominal wall was confirmed during laparoscopic surgery.
RESULTS: The sliding distances in upper right, upper central, upper left, lower right, lower central, and lower left zones in patients with versus without intestinal adhesion were 4.4 versus 1.4 cm (P = .004), 3.4 versus 2.5 cm, 4.3 versus 1.3 cm (P = .011), 3.1 versus 1.5 cm (P = .0014), 3.3 versus 1.1 cm (P = .013), and 3.4 versus 0.8 cm (P = .0061), respectively. Receiver operating characteristic analysis revealed the optimal value of sliding distance as 2.5 cm and the area under the curve as 0.86. The specificity of US assessment of adhesion was lower in the central zone than in lateral zones. Loose adhesion mostly seen around the scar was attributed to either filmy tissue or omental adhesion, leading to visceral sliding during US.
CONCLUSION: This study revealed the reason for insufficient accuracy of preoperative US assessment of intestinal adhesion around the scar area because of loose adhesion. The upper lateral area might be optimal for first port insertion.
Tandem colonoscopies studies results, show that novel endoscopic technologies detect about 20% more adenomas than those conventional colonoscopy does (missed adenomas). Since Endocuff-assisted colonoscopy cannot be considered as a perfect examination, we hypothesize that conventional colonoscopy will detect one third of the missed adenomas that Endocuff-assisted colonoscopy detects in a similar setting. Therefore a sample size of 120 adenomas achieves 80% power to detect an odds ratio of 3.0 using a two-sided McNemar test with a significance level of 0.05. The odds ratio is equivalent to a difference between two paired proportions of 14% which occurs when the proportion of detected missed adenomas during Endocuff-assisted colonoscopy is 21% and the proportion of missed adenomas during conventional colonoscopy is 7%. During one year period before the study initiation, our colonoscopy performance quality data show that we detect a mean number of adenomas per patient equal of 0.7 in a population similar to the one recruited in our study. Therefore, 172 patients overall will be required to detect 120 adenomas. Given the uncertainty of our estimation and in order to cope with patients exclusions, withdrawals and unexpected incomplete colonoscopies, we decided to recruit 200 patients.

A more extensive description regarding the investigators study is provided in the following fields.
The multicenter clinical trial will be conducted using a single-blind method. Stool samples provided by participants will be evaluated by Human Multigene Methylation Detection Kit (Fluorescent PCR). The kit will be used to qualitatively detect methylation levels of multiple genes in human stool samples in vitro by using Quantitative Methylation Specific PCR (qMSP). The principle of the method is as follows. First, the target DNA in human stool is extracted by magnetic bead-capture technology and then treated with sodium bisulfite. The sequence of unmethylated DNA will be changed while that of the methylated DNA remains the same after sodium bisulfite treatment. Subsequently, qMSP is employed to detect methylation levels of target genes in addition to ACTB gene (a reference gene). Controls of ACTB gene with and without methylation are tested simultaneously. Result of qMSP is dichotomized as positive and negative based on Ct value obtained. The test result is then verified by Sanger sequencing and compared with that from colonoscopy examination and pathology report. The main evaluation indexes for test performance are sensitivity, specificity, consistency rate, kappa coefficient.
The use of tropic acid and a derivative thereof in the preparation of a drug for treating psoriasis. It is found that tropic acid and the derivative thereof can significantly improve skin damage of a psoriasis animal model. The tropic acid and the derivative thereof have low toxicity, fast action, a short treatment course, a small dosage, a low recurrence rate and is convenient to use, and the dosage forms for external use, oral administration, injection, etc. are taken into consideration, such that it is possible to adapt to patients with different degrees and different types of psoriasis. It is also found that compounds III and IV obtained by means of structural modification have a significantly better therapeutic effect than tropic acid. The small molecule drugs used are easily obtained, have a low price and stable properties, are convenient to store and transport, and have broad application prospects.
Infusion extravasation has an increased incidence in newborns, which can result in various adverse outcomes. This study aimed to investigate the effects of different types of temperament on infusion extravasation in newborns. A total of 209 newborns aged 4-7 days who were treated with infusion therapy were assessed for temperament type using the neonatal behavioral assessment scale score (NBAS). The 2009 Infusion Nurses Society clinical grading criteria for extravasation were used, and the clinical data of the newborns, such as gestational age and body weight, were collected. Out of 209 newborns assessed, 107 developed infusion extravasations, with an incidence rate of 51.2%. Newborns with intermediate temperament type were more prone to develop infusion extravasation. Newborns with low body weight, amniotic fluid aspiration syndrome, or meconium aspiration syndrome were prone to develop infusion extravasation. Body weight, temperament type of consolability, temperament type of peak of excitement, diseases, general temperament type, and NBAS total scores of the neonates were independent risk factors for infusion extravasation. Thus, different types of temperament can have an impact on neonatal extravasation.
Participants received maximum of 5 treatments of intramuscular injections of BOTOX® (botulinum toxin Type A) into a single lower limb muscles or divided between both lower limb muscles or into the lower limb muscles and/or upper limb muscles at a minimum of 12 weeks apart. Treatment dosing was according to investigator judgment not to exceed a maximum of 8 unit per kilogram (U/kg) of body weight (not to exceed 300 U) in treatment Cycle 1. Dose could be increased to a maximum of 10 U/kg (not to exceed 340 U) in treatment Cycles 2-5. Participants received intramuscular injections of BOTOX® (botulinum toxin Type A) 4 or 8 U/kg into the lower limb in the previous study or were de novo participants who were not enrolled in the previous study.
1.1 Schizophrenia

Quetiapine fumarate tablet is indicated for the treatment of schizophrenia. The efficacy of quetiapine fumarate tablets in schizophrenia was established in three 6-week trials in adults and one 6-week trial in adolescents (13 to 17 years). The effectiveness of quetiapine fumarate tablets for the maintenance treatment of schizophrenia has not been systematically evaluated in controlled clinical trials. [see Clinical Studies (14.1)]

1.2 Bipolar Disorder

Quetiapine fumarate tablet is indicated for the acute treatment of manic episodes associated with bipolar I disorder, both as monotherapy and as an adjunct to lithium or divalproex. Efficacy was established in two 12-week monotherapy trials in adults, in one 3-week adjunctive trial in adults, and in one 3-week monotherapy trial in pediatric patients (10 to 17 years) [see Clinical Studies (14.2)].

Quetiapine fumarate tablet is indicated as monotherapy for the acute treatment of depressive episodes associated with bipolar disorder. Efficacy was established in two 8-week monotherapy trials in adult patients with bipolar I and bipolar II disorder [see Clinical Studies (14.2)].

Quetiapine fumarate tablet is indicated for the maintenance treatment of bipolar I disorder, as an adjunct to lithium or divalproex. Efficacy was established in two maintenance trials in adults. The effectiveness of quetiapine fumarate tablets as monotherapy for the maintenance treatment of bipolar disorder has not been systematically evaluated in controlled clinical trials. [see Clinical Studies (14.2)].

1.3 Special Considerations in Treating Pediatric Schizophrenia and Bipolar I Disorder

Pediatric schizophrenia and bipolar I disorder are serious mental disorders, however, diagnosis can be challenging. For pediatric schizophrenia, symptom profiles can be variable, and for bipolar I disorder, patients may have variable patterns of periodicity of manic or mixed symptoms. It is recommended that medication therapy for pediatric schizophrenia and bipolar I disorder be initiated only after a thorough diagnostic evaluation has been performed and careful consideration given to the risks associated with medication treatment. Medication treatment for both pediatric schizophrenia and bipolar I disorder is indicated as part of a total treatment program that often includes psychological, educational and social interventions.
The participants wear reflectance pulse oximeter for continuous monitoring when carrying out PSG . Oxygen desaturation index (ODI), average blood oxygen saturation, minimum blood oxygen saturation, percentage of blood oxygen saturation less than 90% in the whole recording time (TS90%), fastest heart rate, slowest heart rate and average heart rate are recorded by reflectance pulse oximeter.
Participants receive 18 sessions of Hatha yoga over the course of radiation therapy. Each 45 to 60 minute session guided by an instructor. Participant should attend each session together with their caregiving partner. Some sessions videotaped. At first session, participant given a CD and instructions for practicing Hatha yoga at home. Questionnaire completion at baseline, during radiation therapy, and at completion of radiation therapy.
All participants will have a resting and exercising electrocardiogram (ECG) trace and a lung function test, called spirometry, will be performed. They will take part in a maximal CPET to determine V̇O2 peak. Participants will also have their V̇O2 peak estimated twice, twenty minutes apart, using the VentriJect Seismofit device. A short questionnaire will be administered to explore the acceptability of completing a maximal CPET and having V̇O2 peak estimated using VentriJect Seismofit.